Alzheimer's: 3 pathological pillars
Alzheimer's disease (AD) is the most common form of dementia (70% of cases). In Belgium, ~250,000 people are affected. Three central pathological mechanisms:
- Amyloid plaques: extraneuronal accumulation of amyloid β (Aβ₁₋₄₂) → neurotoxicity, microglial activation
- Neurofibrillary tangles: hyperphosphorylation of tau protein → microtubule collapse → neuronal death
- Neuroinflammation: microglial and astrocytic activation → cerebral TNF-α, IL-1β, IL-6 → enhanced neurotoxicity
Ginger Mechanisms in Alzheimer's
| Target | Role in AD | Ginger Effect |
|---|---|---|
| BACE-1 (β-secretase) | Aβ production | Inhibition → ↓ Aβ production |
| Aβ aggregation | Plaque formation | Direct aggregation inhibition |
| GSK-3β / CDK5 | Tau hyperphosphorylation | Inhibition → normal tau ↑ |
| NF-κB microglial | Neuroinflammation | ↓ cerebral TNF-α, IL-1β |
| BDNF / TrkB | Hippocampal plasticity ↓ | ↑ BDNF → plasticity ↑ |
| Nrf2 / HO-1 | Neuronal oxidative anxiety-<a%20href=" https:>cortisol-natural-relief">stress | ↑ neuronal antioxidant defense |
| AChE | Cholinergic degeneration | Inhibition → ↑ synaptic ACh |
BACE-1 inhibition — anti-amyloid
BACE-1 is the enzyme that cleaves APP (amyloid precursor protein) to produce Aβ. 6-Gingerol, 10-gingerol, and shogaols inhibit BACE-1 dose-dependently in vitro → less Aβ production. In addition, ginger inhibits the auto-aggregation of already formed Aβ → fewer consolidated plaques.
GSK-3β and CDK5 inhibition — anti-tau
GSK-3β and CDK5 are the main kinases that hyperphosphorylate tau. Ginger inhibits GSK-3β (via PI3K/Akt activation → inactivating phosphorylation of GSK-3β) and reduces CDK5 activity → less phosphorylated tau → stabilized microtubules.
BDNF increase and AChE inhibition
BDNF is reduced in early AD stages — correlates with hippocampal memory loss. Ginger increases BDNF via TrkB and CREB → ↑ synaptic plasticity. Shogaols are particularly potent for BDNF elevation in the hippocampus. At the same time, ginger inhibits AChE → more synaptic acetylcholine → maintains cholinergic signal transmission (same mechanism as donepezil).
GIMBER sugar and Alzheimer's: cerebral glycation
- Cerebral AGEs: Fructose generates AGEs that cross the blood-brain barrier → glycation of Aβ and tau proteins → accelerated aggregation
- Cerebral insulin resistance: AD is sometimes called "type 3 diabetes-management-clinical-evidence-2026">diabetes" — sugar → insulin resistance in the brain → neurons starved of energy
- BDNF inhibited: excessive sugar inhibits hippocampal BDNF → accelerated hippocampal atrophy
- NF-κB activated: sugar → systemic NF-κB → enhanced microglial neuroinflammation
❓ FAQ — Ginger and Alzheimer's
Q: Can ginger treat Alzheimer's disease?
A: No. There is no curative treatment for AD. Ginger may contribute to prevention and slowing of progression in early stages, but it does not replace specialized medical care.
Q: When to start ginger for AD prevention?
A: AD develops 20-30 years before symptoms. Prevention is most effective early. Regular ginger consumption (and an anti-inflammatory diet) from age 40-50 onwards makes sense.
Q: Does sugar worsen Alzheimer's?
A: Epidemiological and mechanistic data suggest it does — T2DM doubles the risk of AD, and AGEs/cerebral insulin resistance are confirmed pathogenic factors.
Related articles
Read more about related topics:
- Alzheimer Prevention and Drinks: Sugar Destroys Brain Cells — INTI the Neuroprotective Choice
- Ginger and Brain: Memory, Cognition and Alzheimer's Neuroprotection
- Ginger & Alzheimer Prevention: Neuroprotection, Memory and Cognition in Daily Life
- Ginger & Alzheimer: Neuroprotection, Amyloid Beta and Dementia Prevention
- Ginger and Alzheimer's Disease: Neuroinflammation, Tau & Amyloid
- Ginger and multiple sclerosis: myelination, neuroinflammation and Th17/Treg central — BDNF and NF-κB — INTI
- Ginger and sleep: insomnia, sleep quality and HPA axis — GABA, adenosine, BDNF and melatonin — INTI
- Ginger and depression: MAO-A/B, BDNF/TrkB, HPA axis and neuroplasticity — INTI